Background: Cases of pancreatitis were identified in the eluxadoline clinical
| INTRODUCTION
Eluxadoline (Viberzi) , a peripherally acting mu-opioid receptor agonist, was approved in the United States on May 27, 2015 for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D) in adults. 1 Eluxadoline is also a delta-opioid receptor antagonist and kappa-opioid receptor agonist.
In addition to effects on gut motility and splanchnic pain mediated by opposing activity at mu-and delta-opioid receptors, ligands released by mu-opioid activation can also result in increased sphincter tone within the gastrointestinal (GI) system. 1, 2 The sphincter of Oddi, the muscular sphincter regulating bile and pancreatic secretions into the duodenum, may be affected by this augmentation in sphincter tone. Pathological sphincter of Oddi contractions, previously known as sphincter of Oddi dysfunction (SOD), refers to a group of functional biliary sphincter disorders leading to abdominal pain and elevated liver enzymes or bile duct dilatation in the absence of bile duct stones or other structural abnormalities. 3 Biliary sphincter disorders may rarely lead to obstruction of the flow of pancreatic juices and bile from the common bile duct into the duodenum resulting in pancreatitis; however, this phenomena has been questioned in more recent times and it is unclear whether idiopathic pancreatitis results in or is the result of biliary and pancreatic sphincter hypertension. [4] [5] [6] Clinically, functional biliary sphincter disorders are most frequently observed in patients who have undergone cholecystectomy and has been referred to as the "post-cholecystectomy syndrome," although patients with a gallbladder less frequently can also develop such disorders. 3, [7] [8] [9] Cases of pancreatitis with or without SOD were identified in the eluxadoline clinical development program and were reflected in initial labelling of these events in the warnings and precautions and adverse reactions sections of the eluxadoline product label. 1 In a phase 2 study of 807 patients, four cases of pancreatitis occurred in the eluxadoline treatment arm (n = 595), of which two occurred after only one or two doses of eluxadoline, one occurred after 18 days of therapy, and one occurred 15 days after eluxadoline discontinuation. 10 The study was amended to exclude patients with a history of pancreatitis, biliary duct disease, SOD, alcohol abuse, binge drinking, elevated serum lipase or cholecystectomy. After implementation of the study amendment, no additional cases of pancreatitis occurred. Moreover, two phase 3 studies 11 of 2428 total patients (eluxadoline n = 1619, placebo n = 809) excluded patients with a history of alcohol abuse or binge drinking, pancreatitis, SOD, post-cholecystectomy biliary pain or cholecystitis within the preceding 6 months. However, five (0.3%) of 1666 patients in the safety population developed pancreatitis during treatment with eluxadoline.
An adjudication committee determined one of the five cases of pancreatitis to be associated with SOD in a patient without a gallbladder. Eluxadoline was approved at a dose of 100 mg twice daily for treatment of IBS-D and at a reduced dose of 75 mg twice daily for use in IBS-D patients without a gallbladder. 1 Initial approved labelling also included a contraindication for use in patients with known or suspected biliary duct obstruction or SOD because these patients are at increased risk for sphincter of Oddi spasm. Another listed contraindication was history of alcohol abuse because these patients are at increased risk for acute pancreatitis.
Postmarketing drug safety surveillance is a vital responsibility of the US Food and Drug Administration (FDA). FDA conducts pharmacovigilance based on review of adverse event reports from a variety of sources including, but not limited to, the FDA's MedWatch program, the drug manufacturer, the medical literature and through contact with concerned individuals. The identification of a safety signal or concern typically begins with the search for other cases and the generation of a case series, followed by a comprehensive review to determine whether and what regulatory action(s) are indicated. Our assessment of the reports included demographic information, reason for use, outcome as noted by the reporter, 14 FAERS cases are presented in Table 1 . All 119 cases were associated with a serious outcome per regulatory definition, including one that specified death and 75 that specified hospitalisation. Ninety-seven One patient received both the 75 mg and 100 mg doses of eluxadoline consecutively. The patient was receiving eluxadoline 100 mg prior to the development of pancreatitis and was adjudicated to 100 mg dose group. 
